Released May 4, 2022, after the close
10-Q filed May 4, 2022, 34 days after period end · 0000950170-22-007389
Q1 2022 · 10-Q
Revenue$18.41M$18.41M +65.3% vs Q1 2021+7.9% vs Q4 2021
Net Income-$65.69M-$65.69M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.68-$0.68 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$74,467,000N/M
Operating Cash Flow-$64,613,000N/M
Free Cash Flowderived-$74,697,000N/M
Margins · derived
Operating margin-404.4%+10.3 pt vs Q1 2021
Net margin-356.7%+47.9 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $18.41M | $11.14M | $2.52M | $2.63M |
| Net Income | -$65.69M | -$45.09M | -$33.52M | -$19.76M |
| EPS Diluted | -$0.68 | -$0.48 | -$0.44 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR